ETFs with exposure to CEL-SCI Corp. : October 11, 2017

ETFs with exposure to CEL-SCI Corp.

Here are 5 ETFs with the largest exposure to CVM-US. Comparing the performance and risk of CEL-SCI Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility.

Ticker Fund Name CVM-US Exposure (%) 1 Year Price Performance (%) 1 Year Volatility (%) Net Expense Ratio (%) Number of Holdings
VUS-CN Vanguard US Total Market Index ETF CAD Hedged 0 17.57 8.12 0.15 3526
VUN-CN Vanguard US Total Market Index ETF 0 12.37 10.35 0.15 3526
ITOT-US iShares Core S&P Total U.S. Stock Market ETF 0 18.36 7.89 0.03 3560
VXF-US Vanguard Extended Market ETF 0 19.74 11.08 0.08 3186
VTI-US Vanguard Total Stock Market ETF 0 18.23 7.78 0.04 3586
CVM-US CEL-SCI Corp. 100 -73 0.46 0 1

Use our ETF screener to find ETFs that hold CVM-US along with other stocks

ETFs with exposure to stocks in the same focus area as CEL-SCI Corp..

Here are 5 ETFs with the largest exposure to stocks in the same focus area and region as CVM-US. These ETFs may not have the highest percentage of CEL-SCI Corp., but offer a broader sector/region exposure further minimizing single stock risk. Comparing the performance and risk of CEL-SCI Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility.

Ticker Fund Name CVM-US Exposure (%) Sector Exposure (%) 1 Year Price Performance (%) 1 Year Volatility (%) Net Expense Ratio (%) Number of Holdings
XBI-US SPDR S&P Biotech ETF 0 27 36.59 27.4 0.35 103
FBT-US First Trust NYSE Arca Biotechnology Index Fund 0 25.52 30.79 23.45 0.55 30
ARKG-US ARK Genomic Revolution Multi-Sector ETF 0 25.16 39.68 26.28 0.75 40
PBE-US Powershares Dynamic Biotechnology & Genome Portfolio 0 24.45 22.38 22.9 0.59 31
IBB-US iShares Nasdaq Biotechnology ETF 0 20.81 19.82 20.48 0.47 160
CVM-US CEL-SCI Corp. 100 100 -73 0.46 0 1

Use our natural language search to find ETFs in any focus area

Disclaimer

The information presented in this report has been obtained from sources deemed to be reliable, but AnalytixInsight does not make any representation about the accuracy, completeness, or timeliness of this information. This report was produced by AnalytixInsight for informational purposes only and nothing contained herein should be construed as an offer to buy or sell or as a solicitation of an offer to buy or sell any security or derivative instrument. This report is current only as of the date that it was published and the opinions, estimates, ratings and other information may change without notice or publication. Past performance is no guarantee of future results. Prior to making an investment or other financial decision, please consult with your financial, legal and tax advisors. AnalytixInsight shall not be liable for any party’s use of this report. AnalytixInsight is not a broker-dealer and does not buy, sell, maintain a position, or make a market in any security referred to herein. One of the principal tenets for us at AnalytixInsight is that the best person to handle your finances is you. By your use of our services or by reading any of our reports, you’re agreeing that you bear responsibility for your own investment research and investment decisions. You also agree that AnalytixInsight, its directors, its employees, and its agents will not be liable for any investment decision made or action taken by you and others based on news, information, opinion, or any other material generated by us and/or published through our services. For a complete copy of our disclaimer, please visit our website www.analytixinsight.com.

*Disclaimer : This is as of previous day’s close